Leflunomide
Biosimilars cost effective vs. leflunomide in rheumatoid arthritis
In patients with rheumatoid arthritis who have an inadequate response to methotrexate, a treatment sequence beginning with a biosimilar appeared cost-effective compared with leflunomide, according to data published in JAMA Network Open.
VIDEO: 'Exciting time' for therapeutic options in polymyalgia rheumatica
In this video, Sebastian E. Sattui, MD, MS, discusses currently available and emerging treatment options in polymyalgia rheumatica.
Leflunomide noninferior to azathioprine as lupus nephritis maintenance therapy
Leflunomide is non-inferior to azathioprine in terms of safety and efficacy for lupus nephritis maintenance therapy, according to data published in the Annals of the Rheumatic Diseases.
'Promising treatments' for Sjögren’s syndrome may enter clinical use in 3-5 years
It is likely that one or more “promising treatments” currently being investigated for Sjögren’s syndrome will come into use within the next 3 to 5 years, according to a presenter at the 2021 Congress of Clinical Rheumatology-West.